Advancing MS Treatment: Participate in the REMODEL-2 Clinical Trial in Arizona
Are you living with relapsing multiple sclerosis (RMS) in Arizona or nearby states? Here’s your chance to contribute to a groundbreaking clinical trial that could revolutionize MS treatment. The REMODEL-2 (CLOU064C12302) study, sponsored by Novartis, is now enrolling participants in Arizona and surrounding regions.
About the REMODEL-2 Study
The REMODEL-2 clinical trial is a Phase 3 study designed to evaluate the safety and efficacy of an investigational oral medication, remibrutinib, compared to the FDA-approved drug teriflunomide (Aubagio®). Remibrutinib targets Bruton’s tyrosine kinase (BTK), a key player in immune system dysfunction. By selectively targeting harmful B-cells, it aims to reduce relapses and improve treatment outcomes while minimizing side effects.
Why Participate?
- Contribute to Life-Changing Research: Your involvement could lead to significant advancements in MS treatment, potentially helping millions worldwide.
- Access Cutting-Edge Care: Benefit from expert neurologists and study coordinators while participating in innovative research.
- Be Part of the Solution: This study aims to develop therapies that can better manage RMS relapses and improve quality of life.
Eligibility Criteria
Participants must meet the following requirements:
- Ages 18–55
- Diagnosed with relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS)
- At least one relapse in the past year or two relapses in the past two years, or evidence of active lesions on MRI
- Additional criteria assessed during screening
What to Expect
The study consists of two phases:
- Core Study: Participants will be randomly assigned to receive either remibrutinib or teriflunomide for 30 months, with regular clinic visits and monthly check-ins.
- Extension Phase: Participants completing the core phase may continue with remibrutinib for up to five years, receiving ongoing care and monitoring.
Assessments include:
- MRI scans
- Bloodwork
- Questionnaires to track fatigue, pain, depression, and mobility
Why Arizona Matters
Arizona is home to a thriving research community, and by participating locally, you’ll be contributing to cutting-edge MS research while benefiting from the expertise of world-class neurologists. Residents from California, Nevada, and New Mexico can also access nearby trial sites.
Join Us
Find out if you qualify today by visiting our website: AZNeuroscienceResearch.com. There, you’ll find more details about this study and other exciting research opportunities.
Alternatively, complete the eligibility questionnaire at Focus.MSResearchTrial.com. Participation is voluntary, and you can withdraw at any time.
Spread the Word
Together, we can make a difference in the fight against MS. If you or someone you know is interested in joining the REMODEL-2 trial, contact us today!
#Hashtags to Share the Message
#MSResearch #ArizonaClinicalTrials #RelapsingMS #MultipleSclerosis #NeurologyResearch #Remibrutinib #ClinicalTrialsArizona #AZNeuroscience #MSAwareness
Help us raise awareness and bring hope to the MS community. Visit AZNeuroscienceResearch.com to learn more!
